Skip to main content
Clinical Trials/ITMCTR2022000046
ITMCTR2022000046
Not yet recruiting
Phase 1

Study on the intervention and management model of metabolic syndrome complicated with hyperuricemia based on ''state'' identification --Study on comprehensive intervention in acute stage of metabolic syndrome complicated with gout

Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Metabolic syndrome\Gout
Sponsor
Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational study
Sex
All

Investigators

Sponsor
Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Meet the diagnostic criteria of gouty arthritis and metabolic syndrome in western medicine; (2\) It conforms to the standard of dampness heat stasis syndrome in TCM; (3\) Acute course of disease, the time from this attack to treatment is within 1 week; (4\) The patient is over 18 years old; (5\) After full notification, the patient is willing to cooperate with relevant diagnosis and treatment and sign the informed consent.

Exclusion Criteria

  • (1\) Secondary hyperuricemia and Gout Caused by some systemic diseases or drugs, such as myeloproliferative diseases and gouty arthritis caused by diuretics; (2\) The patient's affected joints were complicated with serious fracture, trauma, traumatic arthritis and other diseases, which affected the curative effect; (3\) Gout has caused severe deformity of affected joints or skin ulceration, affecting the functional judgment and external drug users; (4\) The patient has received or is receiving uric acid lowering treatment, such as oral febusitar, benzbromarone, allopurinol and other drugs; (5\) Patients who are known to be allergic or intolerant to the drugs used for treatment; (6\) Patients with severe cardiovascular, cerebrovascular, blood system, immune system, mental system and other diseases, liver and kidney dysfunction.

Outcomes

Primary Outcomes

Not specified

Similar Trials